initial public offerings (IPOs) trading on American exchanges

Monday, July 14, 2014

Signal Genetics (SGNL) began trading on the NASDAQ on 18 June 2014

  • As of February 13, 2017, Signal Genetics, Inc. was acquired by miRagen Therapeutics, Inc.,  a privately-held biopharmaceutical company, in a reverse merger transaction. 
  • The combined company is named Miragen Therapeutics and trades under the ticker "MGEN."



Description

Signal Genetics, Inc. is a commercial-stage, molecular diagnostic company focused on providing diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. It develops, validates and delivers diagnostic services that enable better patient-care decisions.

Address

14TH FLOOR, 667 MADISON AVE.
NEW YORK, NY 10065
United States

Key stats and ratios

Q1 (Mar '14)2013
Net profit margin-64.70%-50.03%
Operating margin-15.28%-4.55%
EBITD margin--6.90%
Return on average assets-78.99%-66.93%
Return on average equity--
Employees14

No comments:

Post a Comment